Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer47
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer46
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review30
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis27
Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance20
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance18
Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer17
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics17
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment17
Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study16
Table of Contents16
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations16
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans14
Editorial Board13
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response12
Role of neoadjuvant pembrolizumab in advanced melanoma12
Military exposures and lung cancer in United States Veterans12
Editorial Board11
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer10
Editorial Board10
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis10
Masthead10
Masthead9
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)9
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review9
Acute liver failure secondary to malignant infiltration: A single center experience9
The effects of microbiota-derived short-chain fatty acids on T lymphocytes: From autoimmune diseases to cancer9
Masthead9
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer8
Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment8
Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use8
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review8
The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.8
Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities8
Lactylation in radiosensitivity regulation: Mechanistic insights and recent advances8
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population7
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care7
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward7
Barriers and facilitators to lung cancer screening and follow-up6
Current and prospective antibody-based therapies in multiple myeloma6
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in t6
Multiple myeloma: Insights into underlying mechanisms, advances in diagnostic and therapeutic modalities6
Editorial Board6
A narrative review of the principal glucocorticoids employed in cancer6
MicroRNAs: From Bench to Bedside Applications as Breast Cancer Therapeutics5
outside front cover5
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges5
Masthead5
Recent updates on novel heterocyclic scaffolds of anticancer potential as emerging tubulin inhibitors5
Radiation recall dermatitis: A review of the literature5
Editorial Board5
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects5
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy5
Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications5
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment4
Daratumumab: A review of current indications and future directions4
Are we there yet? Gut microbiota for cancer diagnosis, prognosis and treatment4
Masthead4
Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data4
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty4
Masthead4
0.18164300918579